175 related articles for article (PubMed ID: 28471808)
1. 3-Bromopyruvate enhances TRAIL-induced apoptosis in human nasopharyngeal carcinoma cells through CHOP-dependent upregulation of TRAIL-R2.
Can Z; Lele S; Zhirui Z; Qiong P; Yuzhong C; Lingling L; Surong Z; Yiming S; Pei Z; Chenchen J; Liu H
Anticancer Drugs; 2017 Aug; 28(7):739-749. PubMed ID: 28471808
[TBL] [Abstract][Full Text] [Related]
2. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5.
Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H
Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536
[TBL] [Abstract][Full Text] [Related]
3. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway.
Yi L; Zongyuan Y; Cheng G; Lingyun Z; Guilian Y; Wei G
Cancer Sci; 2014 May; 105(5):520-7. PubMed ID: 24612139
[TBL] [Abstract][Full Text] [Related]
4. Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
Moon DO; Asami Y; Long H; Jang JH; Bae EY; Kim BY; Choi YH; Kang CH; Ahn JS; Kim GY
Toxicol In Vitro; 2013 Feb; 27(1):257-63. PubMed ID: 22982206
[TBL] [Abstract][Full Text] [Related]
5. Oligomycin A enhances apoptotic effect of TRAIL through CHOP-mediated death receptor 5 expression.
He L; Jang JH; Choi HG; Lee SM; Nan MH; Jeong SJ; Dong Z; Kwon YT; Lee KS; Lee KW; Chung JK; Ahn JS; Kim BY
Mol Carcinog; 2013 Feb; 52(2):85-93. PubMed ID: 23335397
[TBL] [Abstract][Full Text] [Related]
6. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells.
Jung KJ; Min KJ; Bae JH; Kwon TK
Oncotarget; 2015 Jan; 6(3):1556-68. PubMed ID: 25596735
[TBL] [Abstract][Full Text] [Related]
7. Tunicamycin enhances human colon cancer cells to TRAIL-induced apoptosis by JNK-CHOP-mediated DR5 upregulation and the inhibition of the EGFR pathway.
Guo X; Meng Y; Sheng X; Guan Y; Zhang F; Han Z; Kang Y; Tai G; Zhou Y; Cheng H
Anticancer Drugs; 2017 Jan; 28(1):66-74. PubMed ID: 27603596
[TBL] [Abstract][Full Text] [Related]
8. Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: involvement of ROS-dependent ER-stress.
Moon DO; Park SY; Choi YH; Ahn JS; Kim GY
Biochem Pharmacol; 2011 Dec; 82(11):1641-50. PubMed ID: 21903093
[TBL] [Abstract][Full Text] [Related]
9. [Thioridazine Sensitizes Apoptotic Effect of TRAIL in Human Lung Cancer PC9 Cells Through ER Stress Mediated Up-regulation of DR5].
Li J; Wang Y; Liu L; Yuan Y; Bao Y
Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):80-87. PubMed ID: 28228218
[TBL] [Abstract][Full Text] [Related]
10. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation.
Ma Z; Fan C; Yang Y; Di S; Hu W; Li T; Zhu Y; Han J; Xin Z; Wu G; Zhao J; Li X; Yan X
Sci Rep; 2016 Oct; 6():35196. PubMed ID: 27731378
[TBL] [Abstract][Full Text] [Related]
11. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
12. A formulated red ginseng extract upregulates CHOP and increases TRAIL-mediated cytotoxicity in human hepatocellular carcinoma cells.
Lee YS; Lee DG; Lee JY; Kim TR; Hong SS; Kwon SW; Kim YS
Int J Oncol; 2013 Aug; 43(2):591-9. PubMed ID: 23708152
[TBL] [Abstract][Full Text] [Related]
13. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
Na YJ; Lee DH; Kim JL; Kim BR; Park SH; Jo MJ; Jeong S; Kim HJ; Lee SY; Jeong YA; Oh SC
Int J Biochem Cell Biol; 2017 Aug; 89():147-156. PubMed ID: 28624529
[TBL] [Abstract][Full Text] [Related]
14. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
Fujiwara J; Sowa Y; Horinaka M; Koyama M; Wakada M; Miki T; Sakai T
Int J Oncol; 2012 May; 40(5):1483-91. PubMed ID: 22328338
[TBL] [Abstract][Full Text] [Related]
15. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
18. Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP.
Jeon MY; Min KJ; Woo SM; Seo SU; Choi YH; Kim SH; Kim DE; Lee TJ; Kim S; Park JW; Kwon TK
Molecules; 2018 Nov; 23(11):. PubMed ID: 30463333
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid phenethyl ester enhances TRAIL-mediated apoptosis via CHOP-induced death receptor 5 upregulation in hepatocarcinoma Hep3B cells.
Dilshara MG; Jayasooriya RG; Park SR; Choi YH; Choi IW; Kim GY
Mol Cell Biochem; 2016 Jul; 418(1-2):13-20. PubMed ID: 27260301
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells.
Lee JY; Jung KH; Morgan MJ; Kang YR; Lee HS; Koo GB; Hong SS; Kwon SW; Kim YS
Mol Cancer Ther; 2013 Mar; 12(3):274-85. PubMed ID: 23053497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
